Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2022-02-17 00:00:00 ET · period of report 2022-02-15 · accession 0001104659-22-024841 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-17 | 2022-02-15 | PTGX | Kalkofen Donald A. | CFO | A - Grant | $0.00 | +7,500 | 18.5K | +68% | $0 |
| D | 2022-02-17 | 2022-02-15 | PTGX | Kalkofen Donald A. | CFO | A - Grant | $0.00 | +45.0K | 45.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-15 | A | A | 7,500 | $0.00 | 18,521 | D | — | — | (F1) Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025. (F2) Includes an aggregate of 635 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021. |
| 2 | Derivative | Stock Option (right to buy) | 2022-02-15 | A | A | 45,000 | $0.00 | 45,000 | D | $28.73 · — to 2032-02-14 | 45,000 Common Stock | (F3) The stock option vests in 48 equal monthly installments following the date of grant. |